Kyverna Therapeutics (KYTX) Short-term Investments (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Short-term Investments data on file, last reported at $204.3 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 9.94% year-over-year to $204.3 million; the trailing twelve-month figure through Mar 2026 stood at $204.3 million (up 9.94% YoY), and the FY2025 full-year result was $155.2 million, down 18.06% from the prior year.
• Short-term Investments for Q1 2026 stood at $204.3 million, up from $155.2 million in the prior quarter.
• Across five years, Short-term Investments topped out at $216.9 million in Q3 2024 and bottomed at $22.9 million in Q4 2023.
• The 4-year median for Short-term Investments is $172.0 million (2025), against an average of $163.0 million.
• The widest annual swing landed in 2024, when Short-term Investments surged 727.04%; it then tumbled 36.84% in 2025.
• A 4-year view of Short-term Investments shows it stood at $22.9 million in 2023, then soared by 727.04% to $189.4 million in 2024, then retreated by 18.06% to $155.2 million in 2025, then soared by 31.64% to $204.3 million in 2026.
• The last three Short-term Investments figures came in at $204.3 million (Q1 2026), $155.2 million (Q4 2025), and $137.0 million (Q3 2025), per Business Quant data.

Peer Comparison